{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:34:39Z","timestamp":1788568479627,"version":"build-2803163510"},"reference-count":131,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>There is a lack of robust evidence regarding immunosuppressive therapy in children and adolescents after kidney transplantation (KTx), and as such, international practice is highly variable. Recent clinical practice recommendations advocating individualized immunosuppressive strategies that incorporate newer agents are often not implemented. This can potentially contribute to reduced patient and renal allograft survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>The guideline was developed between January 1, 2024, and December 12, 2025, according to the Guidance Manual of the German Association of Scientific Medical Societies by the German Societies for Pediatric Nephrology, Nephrology, Transplantation, and Pediatrics, the German Kidney Association, the International Pediatric Transplant Association, the European Society for Pediatric Nephrology and the Members of the Cooperative European Pediatric Renal Transplant Initiative.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>This evidence- and consensus-based guideline provides up-to-date, state-of-the-art recommendations for immunosuppressive therapy after KTx in pediatric kidney transplant recipients. It is based on the best available evidence and the consensus of the relevant German Medical Societies, Members of the Cooperative European Paediatric Renal Transplant Initiative, and the working group on transplantation of the European Society for Paediatric Nephrology, and the International Pediatric Transplant Association.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>The formal consensus reached is particularly significant in cases of weak or inconclusive evidence and where recommendations are based solely on expert opinion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000005772","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T20:00:27Z","timestamp":1781726427000},"page":"e1889-e1915","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Evidence- and Consensus-based European Guideline for Immunosuppressive Therapy After Pediatric Kidney Transplantation"],"prefix":"10.1097","volume":"110","author":[{"given":"Anna","family":"Gr\u00fcnewald","sequence":"first","affiliation":[{"name":"Department of Pediatrics II, University Hospital of Essen, Essen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thurid","family":"Ahlenstiel-Grunow","sequence":"additional","affiliation":[{"name":"Department of Pediatrics II, University Hospital of Essen, Essen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Arslan","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust and NIHR Great Ormond Street Hospital Biomedical Research Centre, University College London Great Ormond Street Institute of Child Health, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Battelino","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Children\u2019s Hospital, University Medical Center Ljubljana, Ljubljana, Slovenia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea-Liana Bot","family":"Rachisan","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, University of Medicine and Pharmacy \u201cIuliu Ha\u0163ieganu,\u201d Cluj-Napoca, Romania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Bouts","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Emma Children\u2019s Hospital, Amsterdam University Medical Center, Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Busutti","sequence":"additional","affiliation":[{"name":"Nephrology Unit, Bambino Ges\u00f9 Pediatric Hospital IRCCS, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Cornelissen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Radboudumc Amalia Children\u2019s Hospital, Nijmegen, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huib","family":"de Jong","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Erasmus University Rotterdam, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Dudley","sequence":"additional","affiliation":[{"name":"Department of Paediatric Nephrology, University Hospitals Bristol and Weston NHS Trust, Bristol, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"D\u00fczova","sequence":"additional","affiliation":[{"name":"Department of Paediatric Nephrology, University Hospitals Bristol and Weston NHS Trust, Bristol, United Kingdom."},{"name":"Department of Paediatric Nephrology, Hacettepe University Faculty of Medicine, Ankara, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Eibensteiner","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology and Gastroenterology, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Fichtner","sequence":"additional","affiliation":[{"name":"Department of Pediatrics I, Heidelberg University, Medical Faculty Heidelberg, University Children\u2019s Hospital, Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svitlana","family":"Fomina","sequence":"additional","affiliation":[{"name":"Department of Paediatric Nephrology, Institute of Nephrology of NAMS of Ukraine, Kiev, Ukraine."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes Lopez","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Vall D\u2019Hebron University Hospital, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Gulhan","sequence":"additional","affiliation":[{"name":"Department of Paediatric Nephrology, Hacettepe University Faculty of Medicine, Ankara, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Grabitz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Kidney, Liver, Metabolic and Neurological Diseases, Hannover Medical School, Hannover, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Hogan","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, University Hospital Robert Debr\u00e9, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"H\u00f6cker","sequence":"additional","affiliation":[{"name":"Department of Pediatrics I, Heidelberg University, Medical Faculty Heidelberg, University Children\u2019s Hospital, Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Jeruschke","sequence":"additional","affiliation":[{"name":"Department of Pediatrics II, University Hospital of Essen, Essen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nele","family":"Kanzelmeyer","sequence":"additional","affiliation":[{"name":"Department of Pediatric Kidney, Liver, Metabolic and Neurological Diseases, Hannover Medical School, Hannover, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon Jim","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Children\u2019s Hospital Nottingham, Nottingham, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Korst","sequence":"additional","affiliation":[{"name":"Bundesverband Niere, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaela","family":"Labbadia","sequence":"additional","affiliation":[{"name":"Nephrology Unit, Bambino Ges\u00f9 Pediatric Hospital IRCCS, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieczys\u0142aw","family":"Litwin","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kidney Transplantation and Hypertension, Children\u2019s Memorial Health Institute, Warsaw, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Marks","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust and NIHR Great Ormond Street Hospital Biomedical Research Centre, University College London Great Ormond Street Institute of Child Health, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Melk","sequence":"additional","affiliation":[{"name":"Department of Pediatric Kidney, Liver, Metabolic and Neurological Diseases, Hannover Medical School, Hannover, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Novljan","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Children\u2019s Hospital, University Medical Center Ljubljana, Ljubljana, Slovenia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Obrycki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kidney Transplantation and Hypertension, Children\u2019s Memorial Health Institute, Warsaw, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Pape","sequence":"additional","affiliation":[{"name":"Institute of Physiology II, University of Muenster, Muenster, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pasini","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, IRCCS Ospedale Maggiore Policlinico Sant\u2019Orsola, Pediatric Clinic, University of Bologna, Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Patry","sequence":"additional","affiliation":[{"name":"Department of Pediatrics I, Heidelberg University, Medical Faculty Heidelberg, University Children\u2019s Hospital, Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Pohl","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, University Hospital Freiburg, Freiburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenia","family":"Preka","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM U970 PARCC, Paris Institute for Transplantation and Organ Regeneration, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Prytula","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology and Rheumatology, Ghent University Hospital, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Rieger","sequence":"additional","affiliation":[{"name":"Department of Pediatrics I, Heidelberg University, Medical Faculty Heidelberg, University Children\u2019s Hospital, Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Schiffer","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology and Hypertension, University Hospital of Erlangen, Erlangen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Schild","sequence":"additional","affiliation":[{"name":"Institute of Physiology II, University of Muenster, Muenster, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Seeman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Pediatric Nephrology, Prague, Czech Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Stojanovic","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust and NIHR Great Ormond Street Hospital Biomedical Research Centre, University College London Great Ormond Street Institute of Child Health, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Testa","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology and Dialysis, Kidney Transplantation Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"T\u00f6nshoff","sequence":"additional","affiliation":[{"name":"Department of Pediatrics I, Heidelberg University, Medical Faculty Heidelberg, University Children\u2019s Hospital, Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diletta Domenica","family":"Torres","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology and Dialysis Unit, Pediatric Hospital Giovanni XXIII, Bari, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz T.","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Children\u00b4s and Adolescents\u00b4 Hospital, University Hospital of Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Nothacker","sequence":"additional","affiliation":[{"name":"Association of the Scientific Medical Societies in Germany, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Pape","sequence":"additional","affiliation":[{"name":"Department of Pediatrics II, University Hospital of Essen, Essen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"R2-20260824","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence.","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R3-20260824","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1097\/TP.0b013e318188af15","article-title":"Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.","volume":"86","author":"Offner","year":"2008","journal-title":"Transplantation"},{"key":"R4-20260824","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00467-008-0931-x","article-title":"Multicentre prospective randomised trial of tacrolimus, azathioprine and prednisolone with or without basiliximab: two-year follow-up data.","volume":"24","author":"Webb","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"R5-20260824","first-page":"8","article-title":"Use of basiliximab with the standard immunosuppressive protocol in pediatric renal transplantation: a double-blind randomized clinical trial.","volume":"11","author":"Shemshadi","year":"2020","journal-title":"Int J Organ Transplant Med"},{"key":"R6-20260824","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.transproceed.2003.10.087","article-title":"Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year.","volume":"35","author":"Duzova","year":"2003","journal-title":"Transplant Proc"},{"key":"R7-20260824","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/petr.12627","article-title":"Outcomes of two-drug maintenance immunosuppression for pediatric renal transplantation: 10-yr follow-up in a single center.","volume":"20","author":"Michael","year":"2016","journal-title":"Pediatr Transplant"},{"key":"R8-20260824","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1399-3046.2007.00764.x","article-title":"Comparison of outcomes with low-dose anti-thymocyte globulin, basiliximab or no induction therapy in pediatric kidney transplant recipients: a retrospective study.","volume":"12","author":"Baron","year":"2008","journal-title":"Pediatr Transplant"},{"key":"R9-20260824","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1399-3046.2005.00267.x","article-title":"Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab.","volume":"9","author":"Ojogho","year":"2005","journal-title":"Pediatr Transplant"},{"key":"R10-20260824","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1097\/TP.0000000000001577","article-title":"Induction therapy, rejection, and graft outcomes in pediatric and adolescent kidney transplant recipients.","volume":"101","author":"Mincham","year":"2017","journal-title":"Transplantation"},{"key":"R11-20260824","doi-asserted-by":"crossref","first-page":"e18641","DOI":"10.5812\/numonthly.18641","article-title":"Effects of interleukin 2 receptor blockers on patient and graft survival in renal-transplanted children.","volume":"6","author":"Sharifian","year":"2014","journal-title":"Nephrourol Mon"},{"key":"R12-20260824","doi-asserted-by":"crossref","first-page":"e0135439","DOI":"10.1371\/journal.pone.0135439","article-title":"Efficacy and safety of an everolimus- vs. a mycophenolate mofetil-based regimen in pediatric renal transplant recipients.","volume":"10","author":"Brunkhorst","year":"2015","journal-title":"PLoS One"},{"key":"R13-20260824","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/j.1600-6143.2006.01367.x","article-title":"A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation.","volume":"6","author":"Grenda","year":"2006","journal-title":"Am J Transplant"},{"key":"R14-20260824","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1399-3046.2010.01335.x","article-title":"Induction therapy in pediatric kidney transplant recipients discharged with a triple drug immunosuppressive regimen.","volume":"14","author":"Sampaio","year":"2010","journal-title":"Pediatr Transplant"},{"key":"R15-20260824","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/tri.12148","article-title":"Longitudinal growth on an everolimus- versus an MMF-based steroid-free immunosuppressive regimen in paediatric renal transplant recipients.","volume":"26","author":"Billing","year":"2013","journal-title":"Transpl Int"},{"key":"R16-20260824","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1399-3046.2009.01222.x","article-title":"Variables affecting estimated glomerular filtration rate after renal transplantation in children: a NAPRTCS data analysis.","volume":"14","author":"Moudgil","year":"2010","journal-title":"Pediatr Transplant"},{"key":"R17-20260824","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/ndt\/17.2.276","article-title":"Single centre experience with basiliximab in paediatric renal transplantation.","volume":"17","author":"Pape","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"R18-20260824","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.transproceed.2013.02.044","article-title":"Rejection is a strong graft survival predictor in live donor pediatric renal transplantation using cyclosporine, mycophenolate mofetil, and steroids: 5-year outcomes in a single Mexican center.","volume":"45","author":"Martinez-Mier","year":"2013","journal-title":"Transplant Proc"},{"key":"R19-20260824","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00467-024-06487-2","article-title":"Incidence, risk factors, management strategies, and outcomes of antibody-mediated rejection in pediatric kidney transplant recipients\u2014a multicenter analysis of the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN).","volume":"40","author":"Fichtner","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"R20-20260824","first-page":"CD003897","article-title":"Interleukin 2 receptor antagonists for kidney transplant recipients.","volume":"2010","author":"Webster","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 3","key":"R21-20260824","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients.","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"R22-20260824","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/TP.0b013e318188ae18","article-title":"Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication.","volume":"86","author":"H\u00f6cker","year":"2008","journal-title":"Transplantation"},{"key":"R23-20260824","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/ajt.13884","article-title":"Induction therapy for kidney transplant recipients: do we still need anti-IL2 receptor monoclonal antibodies?","volume":"17","author":"Hellemans","year":"2017","journal-title":"Am J Transplant"},{"key":"R24-20260824","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1600-6143.2010.03047.x","article-title":"A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study.","volume":"10","author":"Grenda","year":"2010","journal-title":"Am J Transplant"},{"key":"R25-20260824","first-page":"84","article-title":"Nineteen years of experience utilizing anti-T-lymphocyte globulin induction in pediatric kidney transplantation.","volume":"15","author":"Mota","year":"2010","journal-title":"Ann Transplant"},{"key":"R26-20260824","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1600-6143.2006.01675.x","article-title":"Younger age and antibody induction increase the risk for infection in pediatric renal transplantation: a NAPRTCS report.","volume":"7","author":"Puliyanda","year":"2007","journal-title":"Am J Transplant"},{"key":"R27-20260824","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/TP.0b013e318257ad41","article-title":"Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis.","volume":"93","author":"Morgan","year":"2012","journal-title":"Transplantation"},{"key":"R28-20260824","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/01.TP.0000100826.58738.2B","article-title":"Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.","volume":"76","author":"Cherikh","year":"2003","journal-title":"Transplantation"},{"key":"R29-20260824","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/01.tp.0000219817.18049.36","article-title":"Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients.","volume":"81","author":"Opelz","year":"2006","journal-title":"Transplantation"},{"key":"R30-20260824","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/01.TP.0000442773.38510.32","article-title":"Acute rejection, T-cell-depleting antibodies, and cancer after transplantation.","volume":"97","author":"Lim","year":"2014","journal-title":"Transplantation"},{"key":"R31-20260824","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1681\/ASN.2008101037","article-title":"Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients.","volume":"20","author":"No\u00ebl","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R32-20260824","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s13063-015-0891-y","article-title":"Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 study participants.","volume":"16","author":"Lentine","year":"2015","journal-title":"Trials"},{"key":"R33-20260824","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1111\/ajt.13191","article-title":"Daclizumab versus rabbit antithymocyte globulin in high-risk renal transplants: five-year follow-up of a randomized study.","volume":"15","author":"Hellemans","year":"2015","journal-title":"Am J Transplant"},{"key":"R34-20260824","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0161-5890(03)00072-5","article-title":"Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation.","volume":"39","author":"Abou-Jaoude","year":"2003","journal-title":"Mol Immunol"},{"key":"R35-20260824","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/01.TP.0000056635.59888.EF","article-title":"A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients.","volume":"75","author":"Charpentier","year":"2003","journal-title":"Transplantation"},{"key":"R36-20260824","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/TP.0b013e3182472898","article-title":"Influence of induction modality on the outcome of deceased donor kidney transplant recipients discharged on steroid-free maintenance immunosuppression.","volume":"93","author":"Sureshkumar","year":"2012","journal-title":"Transplantation"},{"key":"R37-20260824","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1399-3046.2005.00271.x","article-title":"Improved outcome of pediatric kidney transplantations in the Netherlands\u2014effect of the introduction of mycophenolate mofetil?","volume":"9","author":"Cransberg","year":"2005","journal-title":"Pediatr Transplant"},{"key":"R38-20260824","first-page":"9","article-title":"Graft survival rate in pediatric renal transplantation: a single center experience.","volume":"28","author":"Almasi-Hashiani","year":"2012","journal-title":"Pak J Med Sci"},{"key":"R39-20260824","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/01.tp.0000258587.70166.87","article-title":"Five-year outcome in pediatric patients with mycophenolate mofetil-based renal transplantation.","volume":"83","author":"Jungraithmayr","year":"2007","journal-title":"Transplantation"},{"key":"R40-20260824","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0041-1345(02)03135-4","article-title":"Mycophenolate mofetil without antibody induction in pediatric renal transplantation.","volume":"34","author":"Ojogho","year":"2002","journal-title":"Transplant Proc"},{"key":"R41-20260824","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1016\/j.transproceed.2011.09.101","article-title":"Clinical description and evolution of renal transplant pediatric patients treated with alemtuzumab.","volume":"43","author":"Velez","year":"2011","journal-title":"Transplant Proc"},{"key":"R42-20260824","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1016\/S0041-1345(02)03475-9","article-title":"Pediatric renal transplantation under tacrolimus or cyclosporine immunosuppression and basiliximab induction.","volume":"34","author":"Garcia","year":"2002","journal-title":"Transplant Proc"},{"key":"R43-20260824","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/00007890-200103150-00010","article-title":"Mycophenolate mofetil in pediatric renal transplantation without induction therapy: results after 12 months of treatment. German pediatric renal transplantation study group.","volume":"71","author":"Staskewitz","year":"2001","journal-title":"Transplantation"},{"key":"R44-20260824","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/01.TP.0000045748.95874.64","article-title":"Pediatric renal transplantation with mycophenolate mofetil-based immunosuppression without induction: results after three years.","volume":"75","author":"Jungraithmayr","year":"2003","journal-title":"Transplantation"},{"key":"R45-20260824","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1016\/j.transproceed.2005.08.030","article-title":"Mycophenolate mofetil in pediatric renal transplantation.","volume":"37","author":"Otukesh","year":"2005","journal-title":"Transplant Proc"},{"key":"R46-20260824","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20620","article-title":"Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.","volume":"20","author":"Jones-Hughes","year":"2016","journal-title":"Health Technol Assess"},{"key":"R47-20260824","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1399-3046.2005.00334.x","article-title":"Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion.","volume":"9","author":"Filler","year":"2005","journal-title":"Pediatr Transplant"},{"key":"R48-20260824","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00467-001-0795-9","article-title":"Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation.","volume":"17","author":"Trompeter","year":"2002","journal-title":"Pediatr Nephrol"},{"key":"R49-20260824","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/S0041-1345(02)03128-7","article-title":"One-year glomerular filtration rate predicts graft survival in pediatric renal recipients: a randomized trial of tacrolimus vs cyclosporine microemulsion.","volume":"34","author":"Filler","year":"2002","journal-title":"Transplant Proc"},{"key":"R50-20260824","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/petr.12919","article-title":"Infection rates in tacrolimus versus cyclosporine-treated pediatric kidney transplant recipients on a rapid discontinuation of prednisone protocol: 1-year analysis.","volume":"21","author":"Kizilbash","year":"2017","journal-title":"Pediatr Transplant"},{"key":"R51-20260824","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1034\/j.1399-3046.2003.00079.x","article-title":"Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study.","volume":"7","author":"Neu","year":"2003","journal-title":"Pediatr Transplant"},{"key":"R52-20260824","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/ndt\/gfq450","article-title":"Comparison of MMF efficacy and safety in paediatric vs. adult renal transplantation: subgroup analysis of the randomised, multicentre FDCC trial.","volume":"26","author":"H\u00f6cker","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R53-20260824","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40261-017-0594-0","article-title":"Adverse events under tacrolimus and cyclosporine in the first 3 years post-renal transplantation in children.","volume":"38","author":"Lancia","year":"2018","journal-title":"Clin Drug Investig"},{"key":"R54-20260824","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00467-012-2330-6","article-title":"Protocol biopsies in pediatric renal transplant recipients on cyclosporine versus tacrolimus-based immunosuppression.","volume":"28","author":"Aoun","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"R55-20260824","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000347024","article-title":"Steroid withdrawal in pediatric kidney transplant allows better growth, lipids and body composition: a randomized controlled trial.","volume":"79","author":"Mericq","year":"2013","journal-title":"Horm Res Paediatr"},{"key":"R56-20260824","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1111\/j.1600-6143.2012.04145.x","article-title":"Complete steroid avoidance is effective and safe in children with renal transplants: a multicenter randomized trial with three-year follow-up.","volume":"12","author":"Sarwal","year":"2012","journal-title":"Am J Transplant"},{"key":"R57-20260824","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/j.1600-6143.2009.02640.x","article-title":"Steroid-free immunosuppression since 1999: 129 pediatric renal transplants with sustained graft and patient benefits.","volume":"9","author":"Li","year":"2009","journal-title":"Am J Transplant"},{"key":"R58-20260824","doi-asserted-by":"crossref","first-page":"e13925","DOI":"10.1111\/petr.13925","article-title":"Primary pediatric live-donor-kidney transplant-recipients\u2019 outcomes by immunosuppression induction received in the United States.","volume":"25","author":"Riad","year":"2021","journal-title":"Pediatr Transplant"},{"key":"R59-20260824","doi-asserted-by":"crossref","first-page":"e13928","DOI":"10.1111\/petr.13928","article-title":"Primary pediatric deceased-donor kidney transplant recipients outcomes by immunosuppression induction received in the United States.","volume":"25","author":"Riad","year":"2021","journal-title":"Pediatr Transplant"},{"key":"R60-20260824","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1007\/s00467-011-1934-6","article-title":"Early steroid withdrawal in pediatric renal transplant: five years of follow-up.","volume":"26","author":"Delucchi","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"R61-20260824","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1111\/j.1600-6143.2012.04278.x","article-title":"Outcomes of steroid-avoidance protocols in pediatric kidney transplant recipients.","volume":"12","author":"Nehus","year":"2012","journal-title":"Am J Transplant"},{"key":"R62-20260824","first-page":"1393","article-title":"Early steroid withdrawal in pediatric renal transplantation.","volume":"134","author":"Delucchi","year":"2006","journal-title":"Rev Med Chil"},{"key":"R63-20260824","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/petr.12633","article-title":"Improved cardiovascular risk factors in pediatric renal transplant recipients on steroid avoidance immunosuppression: a study of the Midwest Pediatric Nephrology Consortium.","volume":"20","author":"Weaver","year":"2016","journal-title":"Pediatr Transplant"},{"key":"R64-20260824","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1399-3046.2007.00884.x","article-title":"Potential influence of tacrolimus and steroid avoidance on early graft function in pediatric renal transplantation.","volume":"12","author":"Li","year":"2008","journal-title":"Pediatr Transplant"},{"key":"R65-20260824","doi-asserted-by":"crossref","first-page":"e13717","DOI":"10.1111\/petr.13717","article-title":"Re-hospitalization after pediatric kidney transplant: a single-center study.","volume":"24","author":"Verghese","year":"2020","journal-title":"Pediatr Transplant"},{"key":"R66-20260824","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1399-3046.2008.00928.x","article-title":"Can pediatric steroid-free renal transplantation improve growth and metabolic complications?","volume":"12","author":"Bhakta","year":"2008","journal-title":"Pediatr Transplant"},{"key":"R67-20260824","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dialis.2011.06.002","article-title":"Evaluation of live-donor kidney transplant survival in low body weight Egyptian children: 25 year-experience.","volume":"33","author":"Mosaad","year":"2012","journal-title":"Di\u00e1lisis y Trasplante"},{"key":"R68-20260824","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1111\/j.1600-6143.2012.04144.x","article-title":"Subclinical inflammation and chronic renal allograft injury in a randomized trial on steroid avoidance in pediatric kidney transplantation.","volume":"12","author":"Naesens","year":"2012","journal-title":"Am J Transplant"},{"key":"R69-20260824","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1093\/ndt\/gfx193","article-title":"Graft survival of pediatric kidney transplant recipients selected for de novo steroid avoidance\u2014a propensity score-matched study.","volume":"32","author":"Nehus","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"R70-20260824","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1097\/TP.0000000000000498","article-title":"Corticosteroid-free kidney transplantation improves growth: 2-year follow-up of the TWIST randomized controlled trial.","volume":"99","author":"Webb","year":"2015","journal-title":"Transplantation"},{"key":"R71-20260824","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/ajt.16005","article-title":"Three-year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal.","volume":"21","author":"T\u00f6nshoff","year":"2021","journal-title":"Am J Transplant"},{"key":"R72-20260824","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/ajt.13649","article-title":"Impact of everolimus and low-dose cyclosporin on cytomegalovirus replication and disease in pediatric renal transplantation.","volume":"16","author":"H\u00f6cker","year":"2016","journal-title":"Am J Transplant"},{"key":"R73-20260824","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/ajt.15081","article-title":"Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: results of a randomized trial.","volume":"19","author":"T\u00f6nshoff","year":"2019","journal-title":"Am J Transplant"},{"key":"R74-20260824","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1399-3046.2010.01399.x","article-title":"Protocol biopsy-driven interventions after pediatric renal transplantation.","volume":"14","author":"Kanzelmeyer","year":"2010","journal-title":"Pediatr Transplant"},{"key":"R75-20260824","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1432-2277.2004.tb00426.x","article-title":"Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients.","volume":"17","author":"Holmes","year":"2004","journal-title":"Transpl Int"},{"key":"R76-20260824","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/ndt\/gfp506","article-title":"Improved growth and cardiovascular risk after late steroid withdrawal: 2-year results of a prospective, randomised trial in paediatric renal transplantation.","volume":"25","author":"H\u00f6cker","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R77-20260824","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1600-6143.2009.02767.x","article-title":"A randomized double-blind, placebo controlled trial of steroid withdrawal after pediatric renal transplantation.","volume":"10","author":"Benfield","year":"2010","journal-title":"Am J Transplant"},{"key":"R78-20260824","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1600-6143.2008.02167.x","article-title":"Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids.","volume":"8","author":"McDonald","year":"2008","journal-title":"Am J Transplant"},{"key":"R79-20260824","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/TP.0b013e31819b6d4a","article-title":"Prospective, randomized trial on late steroid withdrawal in pediatric renal transplant recipients under cyclosporine microemulsion and mycophenolate mofetil.","volume":"87","author":"H\u00f6cker","year":"2009","journal-title":"Transplantation"},{"key":"R80-20260824","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/00007890-200009150-00008","article-title":"Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression.","volume":"70","author":"Chakrabarti","year":"2000","journal-title":"Transplantation"},{"key":"R81-20260824","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s004670000335","article-title":"Growth and renal function after steroid-free tacrolimus-based immunosuppression in children with renal transplants.","volume":"14","author":"Ellis","year":"2000","journal-title":"Pediatr Nephrol"},{"key":"R82-20260824","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s00467-007-0576-1","article-title":"Selective late steroid withdrawal after renal transplantation.","volume":"22","author":"Laube","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"R83-20260824","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/01.TP.0000133536.83756.1F","article-title":"Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years.","volume":"78","author":"H\u00f6cker","year":"2004","journal-title":"Transplantation"},{"key":"R84-20260824","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.1399-3046.2010.01374.x","article-title":"Histological progression of chronic renal allograft injury comparing sirolimus and mycophenolate mofetil-based protocols. A single-center, prospective, randomized, controlled study.","volume":"14","author":"Blydt-Hansen","year":"2010","journal-title":"Pediatr Transplant"},{"key":"R85-20260824","doi-asserted-by":"crossref","first-page":"e14628","DOI":"10.1111\/petr.14628","article-title":"Prevalence of mycophenolate mofetil discontinuation and subsequent outcomes in pediatric kidney transplant recipients: a PNRC study.","volume":"28","author":"Moudgil","year":"2024","journal-title":"Pediatr Transplant"},{"key":"R86-20260824","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1399-3046.2006.00526.x","article-title":"SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity.","volume":"10","author":"H\u00f6cker","year":"2006","journal-title":"Pediatr Transplant"},{"key":"R87-20260824","first-page":"CD005632","article-title":"Steroid avoidance or withdrawal for kidney transplant recipients.","volume":"2016","author":"Haller","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R88-20260824","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1681\/ASN.2020050645","article-title":"Steering transplant immunosuppression by measuring virus-specific T cell levels: the randomized, controlled IVIST trial.","volume":"32","author":"Ahlenstiel-Grunow","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"R89-20260824","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/TP.0b013e318186f98a","article-title":"Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial.","volume":"86","author":"van Gelder","year":"2008","journal-title":"Transplantation"},{"key":"R90-20260824","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/j.1600-6143.2007.01983.x","article-title":"Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation.","volume":"7","author":"Le Meur","year":"2007","journal-title":"Am J Transplant"},{"key":"R91-20260824","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1399-3046.2006.00659.x","article-title":"Low incidence of adverse events in outpatient pediatric renal allograft biopsies.","volume":"11","author":"Birk","year":"2007","journal-title":"Pediatr Transplant"},{"key":"R92-20260824","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/01.TP.0000076097.90123.21","article-title":"Safety and risk stratification of percutaneous biopsies of adult-sized renal allografts in infant and older pediatric recipients.","volume":"76","author":"Vidhun","year":"2003","journal-title":"Transplantation"},{"key":"R93-20260824","doi-asserted-by":"crossref","first-page":"10158","DOI":"10.3389\/ti.2021.10158","article-title":"Complement-binding donor-specific anti-HLA antibodies: biomarker for immunologic risk stratification in pediatric kidney transplantation recipients.","volume":"35","author":"Sigurjonsdottir","year":"2022","journal-title":"Transpl Int"},{"key":"R94-20260824","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1038\/s41598-023-34804-6","article-title":"Comparison of high-dose IVIG and rituximab versus rituximab as a preemptive therapy for de novo donor-specific antibodies in kidney transplant patients.","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"key":"R95-20260824","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.transproceed.2021.05.011","article-title":"Long-term follow-up of renal transplant recipients treated with IVIG for de novo donor-specific antibodies.","volume":"53","author":"Knight","year":"2021","journal-title":"Transplant Proc"},{"key":"R96-20260824","doi-asserted-by":"crossref","first-page":"e0178572","DOI":"10.1371\/journal.pone.0178572","article-title":"Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: results of an observational study.","volume":"12","author":"Matignon","year":"2017","journal-title":"PLoS One"},{"key":"R97-20260824","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/tri.13325","article-title":"Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss\u2014a retrospective study.","volume":"32","author":"Cioni","year":"2019","journal-title":"Transpl Int"},{"key":"R98-20260824","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/j.1432-2277.2012.01544.x","article-title":"IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up.","volume":"25","author":"Billing","year":"2012","journal-title":"Transpl Int"},{"key":"R99-20260824","doi-asserted-by":"crossref","first-page":"1087597","DOI":"10.3389\/fimmu.2022.1087597","article-title":"Case report: Daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of de novo donor-specific antibodies.","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"R100-20260824","doi-asserted-by":"crossref","first-page":"e14534","DOI":"10.1111\/petr.14534","article-title":"Carfilzomib-based antibody mediated rejection therapy in pediatric kidney transplant recipients.","volume":"27","author":"Cody","year":"2023","journal-title":"Pediatr Transplant"},{"key":"R101-20260824","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/ajt.14001","article-title":"Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot randomized controlled trial.","volume":"17","author":"Kulkarni","year":"2017","journal-title":"Am J Transplant"},{"key":"R102-20260824","doi-asserted-by":"crossref","first-page":"101819","DOI":"10.1016\/j.eclinm.2022.101819","article-title":"Optimized immunosuppression to prevent graft failure in renal transplant recipients with HLA antibodies (OuTSMART): a randomised controlled trial.","volume":"56","author":"Stringer","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"8 Suppl 2","key":"R104-20260824","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/TP.0000000000003270","article-title":"Monitoring of donor-specific anti-HLA antibodies and management of immunosuppression in kidney transplant recipients: an evidence-based expert paper.","volume":"104","author":"Crespo","year":"2020","journal-title":"Transplantation"},{"key":"R105-20260824","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1097\/TP.0000000000003543","article-title":"The problem of subclinical antibody-mediated rejection in kidney transplantation.","volume":"105","author":"Filippone","year":"2021","journal-title":"Transplantation"},{"key":"R106-20260824","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1056\/NEJMra1802677","article-title":"Antibody-mediated rejection of solid-organ allografts.","volume":"379","author":"Loupy","year":"2018","journal-title":"N Engl J Med"},{"key":"R107-20260824","doi-asserted-by":"crossref","first-page":"101566","DOI":"10.1016\/j.trim.2022.101566","article-title":"Effect of C1q-binding donor-specific anti-HLA antibodies on the clinical outcomes of patients after renal transplantation: a systematic review and meta-analysis.","volume":"72","author":"Kang","year":"2022","journal-title":"Transpl Immunol"},{"key":"R108-20260824","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1097\/TP.0000000000002566","article-title":"Subclinical antibody-mediated rejection after kidney transplantation: treatment outcomes.","volume":"103","author":"Parajuli","year":"2019","journal-title":"Transplantation"},{"key":"R109-20260824","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/TP.0000000000003095","article-title":"Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the transplantation society working group.","volume":"104","author":"Schinstock","year":"2020","journal-title":"Transplantation"},{"key":"R110-20260824","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"R111-20260824","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future.","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"key":"R112-20260824","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1681\/ASN.0000000772","article-title":"Targeting B cells and plasma cells in glomerular disease.","volume":"36","author":"Ahmad","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"R113-20260824","doi-asserted-by":"crossref","first-page":"e70008","DOI":"10.1111\/petr.70008","article-title":"New immunosuppressants in pediatric kidney transplantation: what\u2019s in the pipeline for kids?","volume":"29","author":"T\u00f6nshoff","year":"2025","journal-title":"Pediatr Transplant"},{"key":"R114-20260824","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1681\/ASN.2018121254","article-title":"Daratumumab in sensitized kidney transplantation: potentials and limitations of experimental and clinical use.","volume":"30","author":"Kwun","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"R115-20260824","doi-asserted-by":"crossref","first-page":"e70116","DOI":"10.1111\/petr.70116","article-title":"Daratumumab for treatment of acute antibody-mediated rejection in a pediatric kidney transplant recipient.","volume":"29","author":"Connolly","year":"2025","journal-title":"Pediatr Transplant"},{"key":"R116-20260824","doi-asserted-by":"crossref","first-page":"e15458","DOI":"10.1111\/tan.15458","article-title":"Daratumumab treatment in six highly sensitised solid organ transplant recipients: a case series and literature review.","volume":"103","author":"Lemal","year":"2024","journal-title":"HLA"},{"key":"R117-20260824","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa2400763","article-title":"A randomized phase 2 trial of felzartamab in antibody-mediated rejection.","volume":"391","author":"Mayer","year":"2024","journal-title":"N Engl J Med"},{"key":"R118-20260824","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/ndt\/gfaf097","article-title":"Antibody-mediated rejection-treatment standard.","volume":"40","author":"B\u00f6hmig","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"R119-20260824","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.2174\/1389200218666171121100716","article-title":"Bortezomib in kidney transplant: current use and perspectives.","volume":"18","author":"Requiao-Moura","year":"2017","journal-title":"Curr Drug Metab"},{"key":"R120-20260824","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/ajt.15613","article-title":"A prospective, iterative, adaptive trial of carfilzomib-based desensitization.","volume":"20","author":"Tremblay","year":"2020","journal-title":"Am J Transplant"},{"key":"R121-20260824","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1093\/ndt\/gfae096","article-title":"Carfilzomib-associated thrombotic microangiopathy: clinical features and outcomes.","volume":"39","author":"Joseph","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"R122-20260824","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00277-020-04062-x","article-title":"Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials.","volume":"99","author":"Ball","year":"2020","journal-title":"Ann Hematol"},{"key":"R123-20260824","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1600-6143.2010.03312.x","article-title":"The histology of solitary renal allografts at 1 and 5 years after transplantation.","volume":"11","author":"Stegall","year":"2011","journal-title":"Am J Transplant"},{"key":"R124-20260824","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1111\/ajt.15397","article-title":"Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.","volume":"19","author":"Glotz","year":"2019","journal-title":"Am J Transplant"},{"key":"R125-20260824","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1097\/TP.0000000000001012","article-title":"De novo anti-HLA DSA characteristics and subclinical antibody-mediated kidney allograft injury.","volume":"100","author":"Yamamoto","year":"2016","journal-title":"Transplantation"},{"key":"R126-20260824","doi-asserted-by":"crossref","first-page":"e13869","DOI":"10.1111\/petr.13869","article-title":"Yield and utility of surveillance kidney biopsies in pediatric kidney transplant recipients at various time points post-transplant.","volume":"25","author":"Landsberg","year":"2021","journal-title":"Pediatr Transplant"},{"key":"R127-20260824","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s00467-020-04624-1","article-title":"Characterizing the frequency of modifiable histological changes observed on surveillance biopsies in pediatric kidney allograft recipients.","volume":"35","author":"Odum","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"R128-20260824","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1097\/TP.0000000000000700","article-title":"From mean fluorescence intensity to C1q-binding: the saga of anti-HLA donor-specific antibodies.","volume":"99","author":"Loupy","year":"2015","journal-title":"Transplantation"},{"key":"R129-20260824","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00467-018-3959-6","article-title":"Benefits and risks of protocol biopsies in pediatric renal transplantation.","volume":"34","author":"Gordillo","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"R130-20260824","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/TP.0b013e31827a19cc","article-title":"Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation.","volume":"95","author":"Tait","year":"2013","journal-title":"Transplantation"},{"key":"R131-20260824","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1097\/TP.0000000000001619","article-title":"Kidney transplant with low levels of DSA or low positive B-flow crossmatch: an underappreciated option for highly sensitized transplant candidates.","volume":"101","author":"Schinstock","year":"2017","journal-title":"Transplantation"},{"key":"R132-20260824","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/TP.0000000000002351","article-title":"Comparison of two Luminex single-antigen bead flow cytometry assays for detection of donor-specific antibodies after renal transplantation.","volume":"103","author":"Bertrand","year":"2019","journal-title":"Transplantation"},{"key":"R133-20260824","doi-asserted-by":"crossref","first-page":"e0249934","DOI":"10.1371\/journal.pone.0249934","article-title":"Intensity of de novo DSA detected by Immucor Lifecodes assay and C3d fixing antibodies are not predictive of subclinical ABMR after kidney transplantation.","volume":"16","author":"Bertrand","year":"2021","journal-title":"PLoS One"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/TP.0000000000005772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:09:42Z","timestamp":1787576982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/TP.0000000000005772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":131,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005772","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]}}}